Gottlieb advises FDA after steroid infection scandal

Fifteen Americans have already died from of fungal meningitis from tainted steroid injections in the past two weeks, and over 200 more have been infected.  Amidst calls for more regulation from politicians, former Federal Drug Administration (FDA) official and AEI scholar Scott Gottlieb, MD, explains in a just-published piece what can–and should—be done by the FDA.

Gottlieb points out:

  • Need new laws? Members of Congress are calling for tighter controls over compounding pharmacies. New laws merit consideration, but we also need to better enforce existing rules and address issues that have created shortages of FDA-approved versions of these medicine.
  • Nudged towards compounding: Among the first policy issues that should be scrutinized is a recent tightening of oversight of the manufacturing of generic versions of sterile injectable drugs. This tightening was rooted in some legitimate concerns that the Food and Drug Administration had about the reliability of the manufacturing facilities. But it has prompted shortages of these drugs. In some cases, the shortages have forced doctors to seek these drugs from more lightly regulated compounding pharmacies.
  • Cost v. Quality: At the same time, the administration has created a contradictory set of policies that has diluted the regulatory authority required to ensure the safety of these compounded medicines. On the one hand, the compounded drugs have been favored for their lower costs, even as there was occasional concern about the drug quality.

Read the full piece here

Scott Gottlieb is is a practicing physician and resident fellow at the American Enterprise Institute. He served in several senior positions at the FDA and as a senior adviser at the Centers for Medicare and Medicaid Services. He is available for interviews and can be reached at scott.gottlieb@aei.org.

For media requests please contact MediaServices@aei.org or 202.862.5829.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Scott
Gottlieb
  • Scott Gottlieb, M.D., a practicing physician, has served in various capacities at the Food and Drug Administration, including senior adviser for medical technology; director of medical policy development; and, most recently, deputy commissioner for medical and scientific affairs. Dr. Gottlieb has also served as a senior policy adviser at the Centers for Medicare & Medicaid Services. 

    Click here to read Scott’s Medical Innovation blog.


    Follow Scott Gottlieb on Twitter.

  • Phone: 202.862.5885
    Email: scott.gottlieb@aei.org
  • Assistant Info

    Name: Kelly Funderburk
    Phone: 202.862.5920
    Email: Kelly.Funderburk@AEI.org

What's new on AEI

image Recovering from tax time blues
image 10 welfare reform lessons
image Let HHS nominee Sylvia Burwell explain Obamacare lie
image Why bold ideas backfire in politics
AEI on Facebook
Events Calendar
  • 14
    MON
  • 15
    TUE
  • 16
    WED
  • 17
    THU
  • 18
    FRI
Wednesday, April 16, 2014 | 10:00 a.m. – 11:00 a.m.
Calling treason by its name: A conversation with Liam Fox

Join us at AEI as the Right Honorable Liam Fox sits down with Marc Thiessen to discuss and debate whether America’s intelligence agencies have infringed on the personal privacy of US citizens.

Event Registration is Closed
Thursday, April 17, 2014 | 4:00 p.m. – 5:00 p.m.
The curmudgeon's guide to getting ahead

How can young people succeed in workplaces dominated by curmudgeons who are judging their every move? At this AEI book event, bestselling author and social scientist Charles Murray will offer indispensable advice for navigating the workplace, getting ahead, and living a fulfilling life.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.